Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of TAK-861 in Central Hypersomnia (Narcolepsy)
2022-002965-13Phase 2Active
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oveporexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and narcolepsy, sponsored by Takeda. Started Dec 2022; status: active.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)narcolepsy
Beyond the preview
Go deeper on 2022-002965-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002965-13.